Pluristem Therapeutics Stock Price, News & Analysis (NASDAQ:PSTI)

$1.40 -0.02 (-1.41 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$1.40
Today's Range$1.40 - $1.44
52-Week Range$1.04 - $2.12
Volume103,165 shs
Average Volume405,924 shs
Market Capitalization$149.74 million
P/E RatioN/A
Dividend YieldN/A
Beta0.09

About Pluristem Therapeutics (NASDAQ:PSTI)

Pluristem Therapeutics logoPluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Receive PSTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PSTI
CUSIPN/A
Phone972-74-710-8607

Debt

Debt-to-Equity RatioN/A
Current Ratio4.79%
Quick Ratio4.79%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.85 million
Price / Sales53.11
Cash FlowN/A
Price / CashN/A
Book Value$0.31 per share
Price / Book4.52

Profitability

Trailing EPS($0.32)
Net Income$-27,810,000.00
Net MarginsN/A
Return on Equity-100.14%
Return on Assets-80.04%

Miscellaneous

Employees183
Outstanding Shares108,110,000

Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics, Inc. (NASDAQ:PSTI) posted its earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). View Pluristem Therapeutics' Earnings History.

When will Pluristem Therapeutics make its next earnings announcement?

Pluristem Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Pluristem Therapeutics.

Where is Pluristem Therapeutics' stock going? Where will Pluristem Therapeutics' stock price be in 2017?

4 brokers have issued 1 year price objectives for Pluristem Therapeutics' stock. Their predictions range from $3.00 to $6.00. On average, they expect Pluristem Therapeutics' stock price to reach $4.38 in the next twelve months. View Analyst Ratings for Pluristem Therapeutics.

What are Wall Street analysts saying about Pluristem Therapeutics stock?

Here are some recent quotes from research analysts about Pluristem Therapeutics stock:

  • 1. According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (11/22/2017)
  • 2. Maxim Group analysts commented, "Summary Pluristem announced that Austria’s regulatory health agency, the Austrian Agency for Health and Food Safety (AGES), has cleared the study to begin enrollment in Austria. The PIII trial is currently enrolling patients in the U.S., U.K., and Germany. Pluristem is focused on showing the benefits of therapy in prolonging the time to an event. If patients can keep a limb a year longer, is the therapy viable and does it create value. We do believe the current statistical plan is well designed to show if a difference exists in the time to event analysis. What will be critical will be if US regulators will accept time to event in place of AFS for approval. It stands to reason that a treatment effect which prolongs time to event, (as is the standard on oncology) could suffice for approval in CLI (Critical Limb Ischemia). i.e. if the treated group keeps limbs longer, is the therapy approvable one and is there benefit? We must also consider changes in the regulatory landscape and what impact the adaptive pathway and 21st Century Act might have on regenerative medicine – cell therapy approval timelines." (7/10/2017)

Who are some of Pluristem Therapeutics' key competitors?

Who are Pluristem Therapeutics' key executives?

Pluristem Therapeutics' management team includes the folowing people:

  • Yaky Yanay, Chairman of the Board, Chief Executive Officer (Age 45)
  • Zalman Aberman, President, Co-Chief Executive Officer, Director (Age 61)
  • Erez Egozi, Chief Financial Officer (Age 49)
  • Doron Shorrer CPA, Lead Independent Director (Age 62)
  • Moria Kwiat, Director (Age 36)
  • Hava Meretzki, Director (Age 46)
  • Israel Ben-Yoram, Independent Director (Age 55)
  • Issac Braun, Independent Director (Age 63)

Who owns Pluristem Therapeutics stock?

Pluristem Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Jane Street Group LLC (0.25%), Psagot Investment House Ltd. (0.12%) and Heritage Investors Management Corp (0.08%). Company insiders that own Pluristem Therapeutics stock include Doron Shorrer, Israel Ben-Yoram, Yaky Yanay and Zami Aberman. View Institutional Ownership Trends for Pluristem Therapeutics.

Who bought Pluristem Therapeutics stock? Who is buying Pluristem Therapeutics stock?

Pluristem Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Psagot Investment House Ltd., Heritage Investors Management Corp and Jane Street Group LLC. Company insiders that have bought Pluristem Therapeutics stock in the last two years include Doron Shorrer, Israel Ben-Yoram, Yaky Yanay and Zami Aberman. View Insider Buying and Selling for Pluristem Therapeutics.

How do I buy Pluristem Therapeutics stock?

Shares of Pluristem Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pluristem Therapeutics' stock price today?

One share of Pluristem Therapeutics stock can currently be purchased for approximately $1.40.

How big of a company is Pluristem Therapeutics?

Pluristem Therapeutics has a market capitalization of $149.74 million and generates $2.85 million in revenue each year. The biotechnology company earns $-27,810,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Pluristem Therapeutics employs 183 workers across the globe.

How can I contact Pluristem Therapeutics?

Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 31905. The biotechnology company can be reached via phone at 972-74-710-8607 or via email at [email protected]


MarketBeat Community Rating for Pluristem Therapeutics (PSTI)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  213 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  325
MarketBeat's community ratings are surveys of what our community members think about Pluristem Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pluristem Therapeutics (NASDAQ:PSTI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.38$4.38$3.83$4.17
Price Target Upside: 208.10% upside208.10% upside223.49% upside195.51% upside

Pluristem Therapeutics (NASDAQ:PSTI) Consensus Price Target History

Price Target History for Pluristem Therapeutics (NASDAQ:PSTI)

Pluristem Therapeutics (NASDAQ:PSTI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2017HC WainwrightReiterated RatingBuy$3.50N/AView Rating Details
11/1/2017Maxim GroupSet Price TargetBuy$3.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$5.00N/AView Rating Details
1/10/2017FBR & CoReiterated RatingBuyN/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Pluristem Therapeutics (NASDAQ:PSTI) Earnings History and Estimates Chart

Earnings by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)

Pluristem Therapeutics (NASDAQ PSTI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018($0.08)N/AView Earnings Details
11/14/2017Q1($0.08)($0.08)ViewN/AView Earnings Details
11/6/2014($0.13)($0.09)$0.10 million$0.10 millionViewN/AView Earnings Details
10/6/2014($0.13)($0.09)ViewN/AView Earnings Details
9/11/2014($0.15)($0.09)$0.10 million$0.09 millionViewN/AView Earnings Details
5/8/2014($0.14)($0.14)$0.20 million$0.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Pluristem Therapeutics (NASDAQ:PSTI) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20181($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pluristem Therapeutics (NASDAQ:PSTI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Pluristem Therapeutics (NASDAQ PSTI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 4.31%
Insider Trades by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)
Institutional Ownership by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)

Pluristem Therapeutics (NASDAQ PSTI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2016Zami AbermanCEOBuy5,000$1.33$6,650.00View SEC Filing  
2/18/2016Yaky YanayCFOBuy5,000$1.20$6,000.00View SEC Filing  
2/16/2016Yaky YanayCFOBuy15,000$0.95$14,250.00View SEC Filing  
2/15/2016Doron ShorrerDirectorBuy12,346$0.81$10,000.26View SEC Filing  
2/12/2016Yaky YanayCFOBuy5,000$0.83$4,150.00View SEC Filing  
2/11/2016Israel Ben-YoramDirectorBuy10,000$0.79$7,900.00View SEC Filing  
2/11/2016Zami AbermanCEOBuy31,000$0.80$24,800.00View SEC Filing  
11/16/2015Yaky YanayCFOBuy10,000$1.52$15,200.00View SEC Filing  
11/16/2015Zami AbermanCEOBuy9,900$1.49$14,751.00View SEC Filing  
9/21/2015Israel Ben-YoramDirectorSell30,000$2.10$63,000.00View SEC Filing  
9/21/2015Yaky YanayCFOBuy10,000$2.11$21,100.00View SEC Filing  
9/21/2015Zami AbermanCEOBuy25,500$2.11$53,805.00View SEC Filing  
9/16/2015Yaky YanayCFOBuy10,000$2.12$21,200.00View SEC Filing  
9/15/2015Zami AbermanCEOBuy25,000$2.11$52,750.00View SEC Filing  
11/11/2014Yaky YanayCOOBuy11,000$2.62$28,820.00View SEC Filing  
11/11/2014Zami AbermanCEOBuy13,000$2.64$34,320.00View SEC Filing  
9/22/2014Yaky YanayCOOBuy11,000$2.95$32,450.00View SEC Filing  
9/22/2014Zami AbermanCEOBuy5,000$2.92$14,600.00View SEC Filing  
9/21/2014Zami AbermanCEOBuy5,000$2.96$14,800.00View SEC Filing  
9/17/2014Israel Ben-YoramDirectorBuy5,000$2.82$14,100.00View SEC Filing  
9/16/2014Boaz Gur-LavieCFOBuy3,478$2.84$9,877.52View SEC Filing  
9/16/2014Yaky YanayCOOBuy10,000$2.85$28,500.00View SEC Filing  
9/16/2014Zami AbermanCEOBuy15,000$2.80$42,000.00View SEC Filing  
6/18/2014Mark GermainDirectorSell43,215$3.12$134,830.80View SEC Filing  
1/17/2014Israel Ben-YoramDirectorSell35,625$4.51$160,668.75View SEC Filing  
1/13/2014Israel Ben-YoramDirectorSell26,453$4.29$113,483.37View SEC Filing  
1/13/2014Yaky YanayCFOSell69,850$4.29$299,656.50View SEC Filing  
1/9/2014Yaky YanayCFOSell30,150$4.25$128,137.50View SEC Filing  
1/8/2014Israel Ben-YoramDirectorSell44,797$4.12$184,563.64View SEC Filing  
11/11/2013Nachum RosmanDirectorSell67,244$3.27$219,887.88View SEC Filing  
9/12/2013Israel Ben-YoramDirectorSell52,000$3.07$159,640.00View SEC Filing  
5/20/2013Israel Ben-YoramDirectorSell45,429$3.03$137,649.87View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pluristem Therapeutics (NASDAQ PSTI) News Headlines

Source:
DateHeadline
Wired News – VistaGen Receives US Patent on Methods for Producing Blood Cells, Platelets, and Bone Marrow Stem CellsWired News – VistaGen Receives US Patent on Methods for Producing Blood Cells, Platelets, and Bone Marrow Stem Cells
finance.yahoo.com - December 12 at 10:46 AM
Pluristem Therapeutics (PSTI) & Protagonist Therapeutics (PTGX) Head to Head ComparisonPluristem Therapeutics (PSTI) & Protagonist Therapeutics (PTGX) Head to Head Comparison
www.americanbankingnews.com - December 11 at 1:36 PM
Pluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematology’s Annual MeetingPluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematology’s Annual Meeting
finance.yahoo.com - December 7 at 10:42 AM
Peer-Reviewed Article Published on Pluristems PLX-PAD Cells Mechanism of Action to Restore Blood Flow in ... - GlobeNewswire (press release)Peer-Reviewed Article Published on Pluristem's PLX-PAD Cells' Mechanism of Action to Restore Blood Flow in ... - GlobeNewswire (press release)
globenewswire.com - November 30 at 4:34 PM
Peer-Reviewed Article Published on Pluristem’s PLX-PAD Cells’ Mechanism of Action to Restore Blood Flow in Ischemic TissuePeer-Reviewed Article Published on Pluristem’s PLX-PAD Cells’ Mechanism of Action to Restore Blood Flow in Ischemic Tissue
finance.yahoo.com - November 29 at 10:24 AM
Comparing Pluristem Therapeutics (PSTI) & The CompetitionComparing Pluristem Therapeutics (PSTI) & The Competition
www.americanbankingnews.com - November 25 at 5:10 PM
Pluristem Therapeutics, Inc. (PSTI) Receives Consensus Recommendation of "Buy" from AnalystsPluristem Therapeutics, Inc. (PSTI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 25 at 1:48 AM
Pluristem Therapeutics (PSTI) Granted US Patent for Skeletal Muscle Regeneration - StreetInsider.comPluristem Therapeutics (PSTI) Granted US Patent for Skeletal Muscle Regeneration - StreetInsider.com
www.streetinsider.com - November 23 at 5:46 PM
Pluristem Therapeutics, Inc. (PSTI) Stock Rating Upgraded by Zacks Investment ResearchPluristem Therapeutics, Inc. (PSTI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 22 at 10:04 PM
Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial HighlightsPluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights
finance.yahoo.com - November 15 at 7:40 AM
Pluristem Therapeutics, Inc. (PSTI) Announces  Earnings ResultsPluristem Therapeutics, Inc. (PSTI) Announces Earnings Results
www.americanbankingnews.com - November 14 at 7:16 AM
Is It Time To Buy Pluristem Therapeutics Inc (PSTI)?Is It Time To Buy Pluristem Therapeutics Inc (PSTI)?
finance.yahoo.com - November 14 at 7:01 AM
Pluristem Therapeutics, Inc. (PSTI) Short Interest UpdatePluristem Therapeutics, Inc. (PSTI) Short Interest Update
www.americanbankingnews.com - November 13 at 2:32 AM
Pluristem reports 1Q lossPluristem reports 1Q loss
finance.yahoo.com - November 9 at 11:59 AM
Pluristem Enters into Agreement with Tel Aviv Sourasky Medical Center to Conduct Phase I/II Trial in Steroid-Refractory Chronic GvHDPluristem Enters into Agreement with Tel Aviv Sourasky Medical Center to Conduct Phase I/II Trial in Steroid-Refractory Chronic GvHD
finance.yahoo.com - November 7 at 9:06 AM
Pluristem Therapeutics, Inc. (PSTI) to Release Earnings on MondayPluristem Therapeutics, Inc. (PSTI) to Release Earnings on Monday
www.americanbankingnews.com - November 6 at 6:54 AM
Pluristem Announces Pricing of Public Offering of Common Stock on the Tel Aviv Stock ExchangePluristem Announces Pricing of Public Offering of Common Stock on the Tel Aviv Stock Exchange
finance.yahoo.com - October 31 at 8:17 AM
Pluristem Therapeutics, Inc. (PSTI) Given Average Recommendation of "Hold" by BrokeragesPluristem Therapeutics, Inc. (PSTI) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 31 at 1:34 AM
Pluristem Proposes to Launch a Public Offering of Common Stock on the Tel Aviv Stock Exchange AfterPluristem Proposes to Launch a Public Offering of Common Stock on the Tel Aviv Stock Exchange After
www.nasdaq.com - October 30 at 6:15 AM
Pluristem Proposes to Launch a Public Offering of Common Stock on the Tel Aviv Stock Exchange After Concluding an Israeli Institutional Investors TenderPluristem Proposes to Launch a Public Offering of Common Stock on the Tel Aviv Stock Exchange After Concluding an Israeli Institutional Investors Tender
feeds.benzinga.com - October 29 at 6:46 PM
Comparing Pluristem Therapeutics (PSTI) and Its RivalsComparing Pluristem Therapeutics (PSTI) and Its Rivals
www.americanbankingnews.com - October 28 at 3:32 PM
Following Approval of Israel’s Ministry of Health, Pluristem Extends its Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery after Bone Marrow Transplant and Opens Clinical Centers in IsraelFollowing Approval of Israel’s Ministry of Health, Pluristem Extends its Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery after Bone Marrow Transplant and Opens Clinical Centers in Israel
finance.yahoo.com - October 27 at 11:52 AM
Pluristem Therapeutics, Inc. (PSTI) PT Set at $3.00 by Maxim GroupPluristem Therapeutics, Inc. (PSTI) PT Set at $3.00 by Maxim Group
www.americanbankingnews.com - October 26 at 1:34 PM
Pluristem Therapeutics (PSTI) Announces European Patent Covering PLX-R18 in Chemotherapy, ARS, Genetic ... - StreetInsider.comPluristem Therapeutics (PSTI) Announces European Patent Covering PLX-R18 in Chemotherapy, ARS, Genetic ... - StreetInsider.com
www.streetinsider.com - October 25 at 9:26 AM
Pluristem Therapeutics (PSTI) Announces European Patent Covering PLX-R18 in Chemotherapy, ARS, Genetic Disorders and Autoimmune DiseasesPluristem Therapeutics (PSTI) Announces European Patent Covering PLX-R18 in Chemotherapy, ARS, Genetic Disorders and Autoimmune Diseases
www.streetinsider.com - October 24 at 8:52 AM
Pluristem Expands its Reach in the Treatment of Impaired Hematopoietic Systems with a European Patent Covering PLX-R18 in Chemotherapy, ARS, Genetic Disorders and Autoimmune DiseasesPluristem Expands its Reach in the Treatment of Impaired Hematopoietic Systems with a European Patent Covering PLX-R18 in Chemotherapy, ARS, Genetic Disorders and Autoimmune Diseases
finance.yahoo.com - October 24 at 8:52 AM
Pluristem Therapeutics, Inc. (PSTI) Given a $2.00 Price Target by Maxim Group AnalystsPluristem Therapeutics, Inc. (PSTI) Given a $2.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - October 19 at 1:08 PM
Pluristem Therapeutics (PSTI) Secures Orphan Drug Designation for Its PLX-R18 Cell Therapy - StreetInsider.comPluristem Therapeutics (PSTI) Secures Orphan Drug Designation for Its PLX-R18 Cell Therapy - StreetInsider.com
www.streetinsider.com - October 19 at 7:48 AM
FDA Grants Pluristem Orphan Drug Designation for Its PLX-R18 Cell Therapy as Treatment for Acute Radiation SyndromeFDA Grants Pluristem Orphan Drug Designation for Its PLX-R18 Cell Therapy as Treatment for Acute Radiation Syndrome
finance.yahoo.com - October 19 at 7:48 AM
Pluristem Therapeutics (PSTI) Says New Published Data Highlights Potential of its PLX Cells in Improving Cardiac ... - StreetInsider.comPluristem Therapeutics (PSTI) Says New Published Data Highlights Potential of its PLX Cells in Improving Cardiac ... - StreetInsider.com
www.streetinsider.com - October 18 at 2:20 AM
New Published Data Highlights the Potential of Pluristems PLX Cells in Improving Cardiac Function in DiabetesNew Published Data Highlights the Potential of Pluristem's PLX Cells in Improving Cardiac Function in Diabetes
finance.yahoo.com - October 17 at 6:31 AM
Pluristem Therapeutics, Inc. (PSTI) Sees Large Increase in Short InterestPluristem Therapeutics, Inc. (PSTI) Sees Large Increase in Short Interest
www.americanbankingnews.com - October 14 at 1:40 AM
Pluristem Therapeutics Inc. (PSTI) Catches Eye: Stock Jumps 5.1% - NasdaqPluristem Therapeutics Inc. (PSTI) Catches Eye: Stock Jumps 5.1% - Nasdaq
www.nasdaq.com - October 12 at 8:33 AM
Todays Research Reports on Trending Tickers: Athersys and Pluristem TherapeuticsToday's Research Reports on Trending Tickers: Athersys and Pluristem Therapeutics
finance.yahoo.com - October 12 at 8:33 AM
Comparing Charles River Laboratories International (CRL) & Pluristem Therapeutics (PSTI)Comparing Charles River Laboratories International (CRL) & Pluristem Therapeutics (PSTI)
www.americanbankingnews.com - October 9 at 2:20 PM
Seaport Global Securities Comments on Pluristem Therapeutics, Inc.s Q3 2018 Earnings (PSTI)Seaport Global Securities Comments on Pluristem Therapeutics, Inc.'s Q3 2018 Earnings (PSTI)
www.americanbankingnews.com - October 9 at 5:34 AM
Seaport Global Securities Reiterates Buy Rating for Pluristem Therapeutics, Inc. (PSTI)Seaport Global Securities Reiterates Buy Rating for Pluristem Therapeutics, Inc. (PSTI)
www.americanbankingnews.com - October 7 at 2:58 PM
Pluristem Therapeutics, Inc. (PSTI) Receives Consensus Rating of "Hold" from BrokeragesPluristem Therapeutics, Inc. (PSTI) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 6 at 9:02 AM
Pluristem Therapeutics (PSTI) Secures $7.9M Grant for nTRACK Collaborative Project Designed to Study Pluristems ... - StreetInsider.comPluristem Therapeutics (PSTI) Secures $7.9M Grant for nTRACK Collaborative Project Designed to Study Pluristem's ... - StreetInsider.com
www.streetinsider.com - October 3 at 11:10 AM
Earnings Review and Free Research Report: Pluristem Announced Fiscal 2017 ResultsEarnings Review and Free Research Report: Pluristem Announced Fiscal 2017 Results
finance.yahoo.com - October 3 at 11:10 AM
$7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristem’s PLX-PAD Cells$7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristem’s PLX-PAD Cells
finance.yahoo.com - October 3 at 11:10 AM
Maxim Group Reiterates $2.00 Price Target for Pluristem Therapeutics, Inc. (PSTI)Maxim Group Reiterates $2.00 Price Target for Pluristem Therapeutics, Inc. (PSTI)
www.americanbankingnews.com - October 2 at 4:30 PM
$7.9 Million Granted To NTRACK Collaborative Project Designed To Study Pluristems PLX-PAD Cells$7.9 Million Granted To NTRACK Collaborative Project Designed To Study Pluristem's PLX-PAD Cells
www.thestreet.com - October 2 at 10:17 AM
Pluristem Therapeutics (PSTI) Says it Received Positive Feedback from FDA and EMA as it Prepares for Phase III Trial ... - StreetInsider.comPluristem Therapeutics (PSTI) Says it Received Positive Feedback from FDA and EMA as it Prepares for Phase III Trial ... - StreetInsider.com
www.streetinsider.com - September 26 at 7:05 PM
Pluristem Receives Positive Feedback from FDA and EMA as Company Prepares for Phase III Trial of PLX-PAD to Support Recovery from Hip FracturePluristem Receives Positive Feedback from FDA and EMA as Company Prepares for Phase III Trial of PLX-PAD to Support Recovery from Hip Fracture
finance.yahoo.com - September 26 at 7:05 PM
FDA Grants Fast Track Designation To Pluristems PLX-PAD For Treatment Of CLIFDA Grants Fast Track Designation To Pluristem's PLX-PAD For Treatment Of CLI
www.rttnews.com - September 20 at 7:59 AM
Corporate News Blog - Nabriva Therapeutics Declares Positive Top-line Results from Phase-3 Clinical Trial Evaluating Lefamulin for the Treatment of CABPCorporate News Blog - Nabriva Therapeutics Declares Positive Top-line Results from Phase-3 Clinical Trial Evaluating Lefamulin for the Treatment of CABP
finance.yahoo.com - September 20 at 7:59 AM
Pluristem Therapeutics (PSTI) Buy Rating Reaffirmed at HC WainwrightPluristem Therapeutics' (PSTI) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - September 19 at 3:14 PM
Pluristem Therapeutics (PSTI) Reports U.S. FDA Grants Fast Track ... - StreetInsider.comPluristem Therapeutics (PSTI) Reports U.S. FDA Grants Fast Track ... - StreetInsider.com
www.streetinsider.com - September 19 at 6:47 AM
Pluristem Wins Key FDA ApprovalPluristem Wins Key FDA Approval
finance.yahoo.com - September 19 at 6:47 AM

SEC Filings

Pluristem Therapeutics (NASDAQ:PSTI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pluristem Therapeutics (NASDAQ:PSTI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pluristem Therapeutics (NASDAQ PSTI) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.